January 2006 Updated 01/01/2006 For the most up-to-date Primary/Preferred Drug List visit www.caremark.com NUCLEOSIDE LUTEINIZING ANTILIPEMICS NITRATES REVERSE- HORMONE- § BILE ACID RESIN SUBLINGUAL ANTIBACTERIALS TRANSCRIPTASE ALKYLATING AGENTS RELEASING HORMONE § CEPHALOSPORIN INHIBITOR (LHRH) AGONISTS CHOLESTEROL § TRANSDERMAL COMBINATIONS ABSORPTION § ERYTHROMYCINS/ INHIBITOR MACROLIDES CENTRAL NERVOUS § FIBRATE SYSTEM§ § FLUOROQUINOLONES NUCLEOTIDE ANTIMETABOLITES § ANTICONVULSANTS § HMG-CoA § ACE INHIBITOR REVERSE- REDUCTASE TRANSCRIPTASE INHIBITORS INHIBITOR ACE INHIBITOR/ MISCELLANEOUS CALCIUM CHANNEL KETOLIDE PROTEASE INHIBITORS BLOCKERS § ANTIFUNGAL § ADRENOLYTIC, § BETA-BLOCKERS ANTIRETROVIRALS FUSION INHIBITOR TYROSINE KINASE INHIBITORS ANGIOTENSIN II § CALCIUM CHANNEL NON-NUCLEOSIDE RECEPTOR ANTIDEMENTIA REVERSE- ANTAGONISTS TRANSCRIPTASE ANTIVIRALS
ATACAND# INHIBITORS HORMONAL CALCIUM CHANNEL § CYTOMEGALOVIRUS ANTINEOPLASTIC BLOCKER/ANTILIPEMIC COMBINATION ANTIANDROGEN § HEPATITIS AGENTS ANGIOTENSIN II § NUCLEOSIDE RECEPTOR ANTIDEPRESSANTS ANTIESTROGENS § DIGITALIS GLYCOSIDE REVERSE- ANTAGONIST § MISCELLANEOUS TRANSCRIPTASE COMBINATIONS INHIBITORS
ATACAND HCT# ENDOTHELIN RECEPTOR AROMATASE MONOAMINE OXIDASE INHIBITORS ANTAGONIST § HERPES AGENT INHIBITORS (MAOIs) § ANTIARRHYTHMICS § INFLUENZA AGENT
FOR YOUR INFORMATION: Generics should be considered the first line of prescribing. The Caremark Primary/Preferred Drug List is not inclusive nor does it guarantee coverage, but represents a summary of prescription coverage. The plan participant's specific prescription benefit plan may have a different co-pay* for specific products on the list. Unless specifically indicated, drug list products will include all dosage forms. To check coverage and co-payments for a specific medicine, log in to www.caremark.com.
Atacand should be reserved for participants who meet CHARM (Candesartan in Heart Failure - Assessment of Reduction in Mortality and Morbidity) trialcriteria. * Co-payment or co-pay means the amount a plan participant is required to pay for a prescription in accordance with a Plan, which may be a deductible,
a percentage of the prescription price, a fixed amount or other charge, with the balance, if any, paid by a Plan. § Generics are available in this class and should be considered as the first line of prescribing. § SELECTIVE § MUSCULOSKELETAL EXTENDED CYCLE RAPAMYCIN SEROTONIN THERAPY AGENT DERIVATIVE REUPTAKE INHIBITORS TRANSDERMAL § ANTIEMETIC § BENIGN PROSTATIC HYPERPLASIA ENDOCRINE AND METABOLIC FOLIC ACID ANDROGENS COMBINATION SEROTONIN ESTROGENS ANTIOBESITY – FAT ERECTILE NOREPINEPHRINE ABSORPTION DYSFUNCTION REUPTAKE INHIBITORS DECREASING AGENT PHOSPHODIESTERASE § PRENATAL VITAMIN (SNRIs)† INHIBITORS ANTIDIABETICS § TRANSDERMAL, ALPHA-GLUCOSIDASE § ANTISPASMODIC ESTROGENS INHIBITOR ALPROSTADIL AGENT ANAPHYLAXIS INSULINS § CHOLELITHOLYTIC § ANTIPARKINSONIAN TREATMENT AGENTS § URINARY ORAL ESTROGEN/ INFLAMMATORY ANTISPASMODICS PROGESTIN BOWEL DISEASE § ANTICHOLINERGICS § ORAL AGENTS ANTIPSYCHOTICS INSULIN SENSITIZERS § RECTAL AGENTS ANTICHOLINERGIC/ INSULIN SENSITIZER/ BETA AGONIST BIGUANIDE FERTILITY REGULATORS § ANTICOAGULANT COMBINATION § LAXATIVE § ATTENTION DEFICIT HYPERACTIVITY MEGLITINIDE PLATELET DISORDER/ ANTIHISTAMINE, LOW PANCREATIC ENZYMES AGGREGATION NARCOLEPSY SEDATING § SULFONYLUREA INHIBITORS
ZYRTEC** SUPPLIES HUMAN GROWTH § ANTIHISTAMINE, HORMONES NONSEDATING
AND KITS‡
ALLEGRA** § PROTON PUMP INHIBITORS IMMUNOMODULATORS § ANTIHISTAMINE/ INTERFERONS DECONGESTANTS HYPNOTIC, NON-
ALLEGRA-D** BENZODIAZEPINE
ZYRTEC-D 12 HOUR** PROTON PUMP BISPHOSPHONATES INHIBITOR WITH § PROGESTIN INTERFERON/ANTIVIRAL § BETA AGONISTS MIGRAINE ANTI-INFECTIVE COMBINATION SELECTIVE SEROTONIN AGONISTS SELECTIVE ESTROGEN § RECTAL STEROID CONTRACEPTIVES RECEPTOR IMMUNOSUPPRESSANTS MODULATOR § MONOPHASIC ANTIMETABOLITES § DECONGESTANT/ SALIVA STIMULANT § BIPHASIC EXPECTORANT MULTIPLE SCLEROSIS § THYROID § CALCINEURIN SUPPLEMENT § TRIPHASIC INHIBITORS LEUKOTRIENE RECEPTOR ANTAGONIST
Indicates the proposed mechanism of action, based on the American Psychiatric Association Summary of Treatment Recommendations.
An Accu-Chek or OneTouch blood glucose meter will be provided at no charge by the manufacturer to those individuals currently using a meter other thanAccu-Chek or OneTouch. For more information on how to obtain a blood glucose meter, call toll-free: 1-800-588-4456. ** Higher co-payments may apply depending on the plan participant’s specific prescription benefit plan. To find the co-payment under a specific plan, log in to www.caremark.com. § Generics are available in this class and should be considered as the first line of prescribing. NASAL ANTIHISTAMINE § LOCAL ANALGESIC § ANTI-INFECTIVE/ CARBONIC ANTI-INFLAMMATORY ANHYDRASE DERMATOLOGY § ROSACEA INHIBITOR/ § NASAL STEROIDS § ANTI-INFLAMMATORY, BETA-BLOCKER STEROIDAL § STEROIDS IMMUNOMODULATOR 1-800-282-2229. § ANTI-INFLAMMATORY, NONSTEROIDAL PROSTAGLANDINS § ACTINIC KERATOSIS STEROID/BETA § ANTIBIOTICS § BETA-BLOCKER, § SYMPATHOMIMETIC NONSELECTIVE MISCELLANEOUS SKIN AND MUCOUS STEROID INHALANTS § ANTIFUNGALS MEMBRANE BETA-BLOCKER, SELECTIVE ANTI-INFECTIVE ANTIPSORIATIC § ANTI-INFECTIVE/ § XANTHINE CARBONIC ANTI-INFLAMMATORY OPHTHALMIC ANHYDRASE § ANTIALLERGICS INHIBITORS IMMUNOMODULATORS § Generics are available in this class and should be considered as the first line of prescribing. ** Higher co-payments may apply depending on the plan participant’s specific prescription benefit plan. To find the co-payment under a specific plan, log in to www.caremark.com.
Caremark may receive rebates, discounts and service fees from pharmaceutical manufacturers for certain listed products.
The Caremark Primary/Preferred Drug List contains prescription brand name medicines that are registered or trademarks of pharmaceutical manufacturers that arenot affiliated with Caremark Inc. Listed products are for informational purposes only and are not intended to replace the clinical judgment of the prescriber. QUICK REFERENCE BRAND PRIMARY/PREFERRED DRUG LIST
ATACAND#
ATACAND HCT#
ALLEGRA**
ALLEGRA-D**
Atacand should be reserved for participants who meet CHARM (Candesartan in Heart Failure - Assessment of Reduction in Mortality and Morbidity) trialcriteria. ** Higher co-payments may apply depending on the plan participant’s specific prescription benefit plan. To find the co-payment under a specific plan, log in to www.caremark.com.
ZYRTEC**
ZYRTEC-D 12 HOUR** ** Higher co-payments may apply depending on the plan participant’s specific prescription benefit plan. To find the co-payment under a specific plan, log in to www.caremark.com.
The Caremark Primary/Preferred Drug List contains prescription brand name medicines that are registered or trademarks of pharmaceutical manufacturers that arenot affiliated with Caremark Inc. Listed products are for informational purposes only and are not intended to replace the clinical judgment of the prescriber.
2006 Caremark Inc. All rights reserved.
www.caremark.com
This is the 11th in a series of 12 articles Non-surgical and drug treatments Stuart Enoch, Joseph E Grey, Keith G Harding Despite great strides in technological innovations and the Treatment emergence of a wide range of treatments for wounds,non-healing wounds continue to perplex and challenge doctors. Various non-surgical approaches have been developed andMedicated bandage su
Nothing to Sneeze at: Skydiving with a Cold or Allergies by Musika Farnsworth Ear or sinus problems at altitude are more than an inconvenience. They can get so intensely painful that they disorient or disable a skydiver in the plane, in freefall or under canopy. Damaged sinuses may take weeks to recover, and ear damage may result in permanent hearing loss or vertigo. “I felt fine